Dare Bioscience, Inc. (DARE): Nasdaq/NYSE listing notice — Dare Bioscience receives Nasdaq delisting notice for failing to meet $35M minimum MVLS rule

Dare Bioscience, Inc.

On Feb 13, 2025, Nasdaq notified Dare Bioscience that its common stock is subject to delisting for failure to regain compliance with the Minimum MVLS Rule by Feb 10, 2025.
The company will request a hearing before the Nasdaq Hearing Panel, which will stay the delisting pending the Panel's decision.
Hearings typically scheduled 30-45 days after request; Panel decision expected within 30 days of hearing; no assurance of extension granted.
Original deficiency notice received Aug 12, 2024; company had 180 days to regain compliance but failed to meet the $35M market value requirement.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Dare Bioscience, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

February 13, 2025, Nasdaq’s Listing Qualifications Department (the “Staff”) notified the Company that because the Company did not timely regain compliance with the Minimum MVLS Rule by February 10, 2025, the Company’s co

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Dare Bioscience, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

February 13, 2025, Nasdaq’s Listing Qualifications Department (the “Staff”) notified the Company that because the Company did not timely regain compliance with the Minimum MVLS Rule by February 10, 2025, the Company’s common stock is subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). The Company will timely request a hearing before the Panel, which request will stay the delisting of the Company’s common stock pending the Panel’s decision following the hearing and the expiration of any extension period that the Panel may

View on SEC.gov

Browse all listing & compliance notices →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-006958

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.